Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide

Nick S R Lan, Umar S Ali, Robert Larbalestier, Girish Dwivedi, P Gerry Fegan

Research output: Contribution to journalLetterpeer-review

Abstract

Patients undergoing coronary artery bypass graft (CABG) surgery require intensive secondary prevention. Semaglutide reduced cardiovascular events in patients with cardiovascular disease and overweight or obesity but without diabetes in the SELECT trial. In this real-world study of 1386 patients without diabetes undergoing CABG surgery in an Australian hospital, approximately 1 in 2 patients (53.3 %) were potentially eligible for semaglutide based on the SELECT trial criteria. These findings highlight that a significant percentage of this very high-risk cohort merit receiving semaglutide for weight management and cardiovascular risk reduction. The implications for optimal care, healthcare costs and clinical guidelines require further evaluation.

Original languageEnglish
Pages (from-to)76-78
Number of pages3
JournalObesity Research & Clinical Practice
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 2024

Fingerprint

Dive into the research topics of 'Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide'. Together they form a unique fingerprint.

Cite this